JP2016185995A5 - - Google Patents

Download PDF

Info

Publication number
JP2016185995A5
JP2016185995A5 JP2016153074A JP2016153074A JP2016185995A5 JP 2016185995 A5 JP2016185995 A5 JP 2016185995A5 JP 2016153074 A JP2016153074 A JP 2016153074A JP 2016153074 A JP2016153074 A JP 2016153074A JP 2016185995 A5 JP2016185995 A5 JP 2016185995A5
Authority
JP
Japan
Prior art keywords
day
disease
compound
use according
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016153074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016185995A (ja
JP6362644B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016185995A publication Critical patent/JP2016185995A/ja
Publication of JP2016185995A5 publication Critical patent/JP2016185995A5/ja
Application granted granted Critical
Publication of JP6362644B2 publication Critical patent/JP6362644B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016153074A 2009-03-19 2016-08-03 高い経口バイオアベイラビリティを有するモルフィナン誘導体 Expired - Fee Related JP6362644B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16170209P 2009-03-19 2009-03-19
US61/161,702 2009-03-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014046328A Division JP2014101388A (ja) 2009-03-19 2014-03-10 高い経口バイオアベイラビリティを有するモルフィナン誘導体

Publications (3)

Publication Number Publication Date
JP2016185995A JP2016185995A (ja) 2016-10-27
JP2016185995A5 true JP2016185995A5 (enExample) 2016-12-28
JP6362644B2 JP6362644B2 (ja) 2018-07-25

Family

ID=42738186

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012500776A Expired - Fee Related JP5555890B2 (ja) 2009-03-19 2009-12-04 高い経口バイオアベイラビリティを有するモルフィナン誘導体
JP2014046328A Pending JP2014101388A (ja) 2009-03-19 2014-03-10 高い経口バイオアベイラビリティを有するモルフィナン誘導体
JP2014097613A Withdrawn JP2014139257A (ja) 2009-03-19 2014-05-09 高い経口バイオアベイラビリティを有するモルフィナン誘導体
JP2016153074A Expired - Fee Related JP6362644B2 (ja) 2009-03-19 2016-08-03 高い経口バイオアベイラビリティを有するモルフィナン誘導体

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2012500776A Expired - Fee Related JP5555890B2 (ja) 2009-03-19 2009-12-04 高い経口バイオアベイラビリティを有するモルフィナン誘導体
JP2014046328A Pending JP2014101388A (ja) 2009-03-19 2014-03-10 高い経口バイオアベイラビリティを有するモルフィナン誘導体
JP2014097613A Withdrawn JP2014139257A (ja) 2009-03-19 2014-05-09 高い経口バイオアベイラビリティを有するモルフィナン誘導体

Country Status (6)

Country Link
US (4) US20100240691A1 (enExample)
EP (2) EP3170395A1 (enExample)
JP (4) JP5555890B2 (enExample)
AU (1) AU2009342654B2 (enExample)
CA (1) CA2754984C (enExample)
WO (1) WO2010107457A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2754984C (en) * 2009-03-19 2018-06-26 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
DK2506712T3 (da) * 2009-12-04 2019-06-03 Alkermes Pharma Ireland Ltd Morfinanderivater til behandling af lægemiddeloverdosering
HRP20240109T1 (hr) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
WO2013088242A1 (en) * 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with opioid agonists
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
PL3153171T3 (pl) * 2011-12-15 2019-02-28 Alkermes Pharma Ireland Limited Samidorfan (alks 33) w połączeniu z buprenorfiną do leczenia zaburzeń depresyjnych
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
WO2014190270A1 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
AU2019309913B2 (en) 2018-07-23 2025-02-27 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
EP4087569A4 (en) 2020-01-10 2024-01-24 Trevi Therapeutics, Inc. METHODS OF ADMINISTRATION OF NALBUPHINE
WO2021178405A1 (en) * 2020-03-02 2021-09-10 University Of Southern California Opioid receptor antagonists
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
WO2025038406A1 (en) * 2023-08-11 2025-02-20 Virginia Commonwealth University Design, synthesis, and biological evaluation of nitrogen-walk derivatives of nan as mu opioid receptor selective modulators

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856795A (en) * 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
US4032529A (en) * 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) * 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4127577A (en) * 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) * 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4649200A (en) * 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5258386A (en) * 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) * 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
NZ326331A (en) * 1996-01-10 2000-01-28 Smithkline Beecham Spa Heterocycle-condensed morphinoid derivatives and medicaments
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
DE60133584T2 (de) * 2000-10-31 2009-06-04 Rensselaer Polytechnic Institute 4-arylpiperidine als opioidrezeptorbindende agenzien
JP5420170B2 (ja) * 2004-05-14 2014-02-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カルボキサミド系オピオイド化合物
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
RU2480455C2 (ru) * 2004-11-05 2013-04-27 Ренссилэйер Политекник Инститьют 4-гидроксибензоморфаны
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
EP1983991A2 (en) * 2006-02-01 2008-10-29 Alkermes, Inc. Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
JP5581211B2 (ja) * 2007-08-09 2014-08-27 レンセラール ポリテクニック インスティチュート 第四級オピオイドカルボキサミド
CA2754984C (en) * 2009-03-19 2018-06-26 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
WO2010141666A2 (en) * 2009-06-04 2010-12-09 The General Hospital Corporation Modulating endogenous beta-endorphin levels
US9211293B2 (en) * 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
JP5929635B2 (ja) * 2012-08-30 2016-06-08 株式会社デンソー 多段式横型鍛造装置

Similar Documents

Publication Publication Date Title
JP2016185995A5 (enExample)
JP2016106150A5 (enExample)
JP2012193216A5 (enExample)
JP2011068653A5 (enExample)
FI3287124T3 (fi) Ketamiinin oraalinen annosmuoto
JP2012255026A5 (enExample)
JP2017506624A5 (enExample)
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2019517542A5 (enExample)
JP2014533272A5 (enExample)
JP2016515628A5 (enExample)
JP2018513188A5 (enExample)
JP2013541583A5 (enExample)
JP2018530578A5 (enExample)
JP2019530706A5 (enExample)
JP2013516493A5 (enExample)
JP2016527312A5 (ja) ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物
JP2018531273A5 (enExample)
JP2012505830A5 (enExample)
JP2011500589A5 (enExample)
JP2016505050A5 (enExample)
JP2018506533A5 (enExample)
JP2017516842A5 (enExample)
JP2014058509A5 (enExample)